Literature DB >> 22392499

ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging.

Tove Olafsen1, Shannon J Sirk, Sebastian Olma, Clifton K-F Shen, Anna M Wu.   

Abstract

Combining the specificity of tumor-targeting antibodies with the sensitivity and quantification offered by positron emission tomography (PET) provides tremendous opportunities for molecular characterization of tumors in vivo. Until recently, significant challenges have been faced when attempting to combine antibodies which show long biological half-lives and positron-emitting radionuclides with comparably short physical half-lives, in particular (18)F (half-life, 109 min). A fast and simple microwave-assisted method of generating N-succinimidyl-4-[(18)F]fluorobenzoate has been developed and employed for radiolabeling a small, rapidly targeting HER2-specific engineered antibody fragment, the cys-diabody. Using this tracer, HER2-positive tumor xenografts in mice were detected at 1-4 h post-injection by microPET. This confirms the rapid kinetics of [(18)F]fluorobenzoyl cys-diabody localization, and demonstrates the feasibility of same-day immunoPET imaging. This approach can be broadly applied to antibodies targeting cell surface biomarkers for molecular imaging of tumors and should be highly translatable for clinical use.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392499     DOI: 10.1007/s13277-012-0365-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

Review 2.  Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications.

Authors:  M Pagani; S Stone-Elander; S A Larsson
Journal:  Eur J Nucl Med       Date:  1997-10

3.  Microwave-assisted one-pot synthesis of N-succinimidyl-4[ ¹⁸F]fluorobenzoate ([¹⁸F]SFB).

Authors:  Shuang Hou; Duy Linh Phung; Wei-Yu Lin; Ming-wei Wang; Kan Liu; Clifton Kwang-Fu Shen
Journal:  J Vis Exp       Date:  2011-06-28       Impact factor: 1.355

4.  Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

Authors:  Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

5.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Authors:  Z Aguilar; R W Akita; R S Finn; B L Ramos; M D Pegram; F F Kabbinavar; R J Pietras; P Pisacane; M X Sliwkowski; D J Slamon
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

6.  Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.

Authors:  G Vaidyanathan; D D Bigner; M R Zalutsky
Journal:  J Nucl Med       Date:  1992-08       Impact factor: 10.057

7.  A novel method of 18F radiolabeling for PET.

Authors:  William J McBride; Robert M Sharkey; Habibe Karacay; Christopher A D'Souza; Edmund A Rossi; Peter Laverman; Chien-Hsing Chang; Otto C Boerman; David M Goldenberg
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

8.  Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.

Authors:  Zhen Cheng; Omayra Padilla De Jesus; Mohammad Namavari; Abhijit De; Jelena Levi; Jack Matt Webster; Rong Zhang; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

9.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

Authors:  R J Pietras; J Arboleda; D M Reese; N Wongvipat; M D Pegram; L Ramos; C M Gorman; M G Parker; M X Sliwkowski; D J Slamon
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

10.  [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.

Authors:  Gabriela Kramer-Marek; Dale O Kiesewetter; Lucia Martiniova; Elaine Jagoda; Sang Bong Lee; Jacek Capala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-22       Impact factor: 9.236

View more
  28 in total

1.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

2.  Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Eftychia Koumarianou; Douglas Weitzel; Takuya Osada; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

Review 3.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

4.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

5.  Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.

Authors:  Scott M Knowles; Kirstin A Zettlitz; Richard Tavaré; Matthew M Rochefort; Felix B Salazar; David B Stout; Paul J Yazaki; Robert E Reiter; Anna M Wu
Journal:  J Nucl Med       Date:  2014-02-06       Impact factor: 10.057

Review 6.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

7.  Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.

Authors:  Keyu Li; Richard Tavaré; Kirstin A Zettlitz; Shannon M Mumenthaler; Parag Mallick; Yu Zhou; James D Marks; Anna M Wu
Journal:  Mol Cancer Ther       Date:  2014-08-20       Impact factor: 6.261

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.

Authors:  Hao Hong; Yin Zhang; Hakan Orbay; Hector F Valdovinos; Tapas R Nayak; Jero Bean; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2013-01-14       Impact factor: 4.939

10.  PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.

Authors:  Yin Zhang; Hao Hong; Hakan Orbay; Hector F Valdovinos; Tapas R Nayak; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.